Sat 25 May 2013
|
Don't miss our
upcoming events
|
|
Brussels, 4-5 Oct. 2012
Preclinical/early clinical biomarker discovery
Vienna, 29 -30 Nov 2012
Present and future breast cancer management: bench to bedside and back
|
_______________________

Disclaimer
|
|
BDA Information
|
|
Click here to request information from BDA
|
Change text size © 2009 Biotherapy Development Association
|
|
BDA Scientific Advisors The BDA Scientific Advisors consists of the following eminent members:

|
Gilles Vassal, MD, PhD, Professor of Oncology, Direction of Clinical and Translational Research, Institut de Cancérologie Gustave-Roussy
|
|
Professor Michel Marty,Director of Centre for Therapeutic Innovation in Oncology and Hematology in Saint Louis University Hospital (Paris, France)
|
|
Prof. Angus Dalgleish, Oncology Division, St George's Medical School, London, UK
|
|
Prof Ian Ellis Professor of Cancer Pathology at the University Hospital, Nottingham, UK
|
|
Dr Steven Hirschfeld - Associate Director Clinical Research, National Institute of Child health and Human Development, Bethesda, USA
|
|
Prof. Pat Price Director of Radiation Oncology, University of Manchester UK
|
|
|
Prof. Bernie Fox Director of Oncology Research, Earle A. Chiles Research Institute, Portland, Oregon, USA
|
|
|
Professor Giampietro Gasparini University Hospital, Rome, Italy
|
|
|
Prof. Gustav Gaudernack Director of Oncology, University of Oslo, Norway
|
|
|
Prof. Rolf Kiessling, Kalrolinska Institute, Stockholm, Sweden
|
|
|
Prof. Klaus Pantel Director Institute for Tumour Biology, University of Hamburg, Germany
|
|
|
Prof. Jamie Zwiebel, Chief for Biologics Evaluation, National Cancer Institute, Maryland, USA
|
|